Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

(2010) Laura Piccio et al.   ARCHIVES OF NEUROLOGY

Neurofilament light as a prognostic marker in multiple sclerosis

(2010) Jonatan Salzer et al.   Multiple Sclerosis Journal

The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)

(2010) Johannes Brettschneider et al.   PLoS One

Prognosis of the individual course of disease: the elements of time, hetereogeneity and precision

(2009) Martin Daumer et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Serum levels of CXCL13 are elevated in active multiple sclerosis

(2009) Eugene D Festa et al.   Multiple Sclerosis Journal

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

(2009) F. Sellebjerg et al.   NEUROLOGY

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

(2008) C. F. Lucchinetti et al.   BRAIN

CSF B – lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis

(2008) U. Ljøstad et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Differential diagnosis of suspected multiple sclerosis: a consensus approach

(2008) DH Miller et al.   Multiple Sclerosis Journal

Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA

(2008) E Iacobaeus et al.   Multiple Sclerosis Journal

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis

(2008) Bettina Kuenz et al.   PLoS One